Expertise in
23
conditions

Dr. Christine Lu-Emerson

Neurology
MH Primary Care Internal And Family Medicine
49 Spring St, 
Scarborough, ME 
Offers Telehealth
Expertise in
23
conditions
MH Primary Care Internal And Family Medicine
49 Spring St, 
Scarborough, ME 

Overview

Christine Lu-Emerson is a Neurologist practicing medicine in Scarborough, Maine.

Dr. Lu-Emerson is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Metastatic Brain Tumor, Glioblastoma, and Glioma.

She is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 7 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in WA

Hospital Affiliations

Mainehealth Maine Medical Center
Northern Light Eastern Maine Medical Center
Maine General Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MH Primary Care Internal and Family Medicine
49 Spring St, Scarborough, ME 04074

Additional Areas of Focus

Dr. Lu-Emerson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Lenalidomide, Methotrexate, Nivolumab, Rituximab
Study Phase: Phase 1
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

16 Total Publications

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 22, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Office

301C US Route 1, 
Scarborough, ME 
 (2.4 miles away)
207-883-1414
Languages Spoken:
English
See accepted insurances

Heidi Henninger is a Neurologist practicing medicine in Scarborough, Maine. Dr. Henninger is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Seizures, Memory Loss, Lennox-Gastaut Syndrome (LGS), and Autosomal Dominant Partial Epilepsy with Auditory Features.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
Before you request

Office

301C US Route 1, 
Scarborough,, ME 
 (2.4 miles away)
207-883-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Megan Selvitelli is a Neurologist practicing medicine in Scarborough,, Maine. Dr. Selvitelli is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Seizures, Progressive Myoclonic Epilepsy, Lafora Disease, and Unverricht-Lundborg Syndrome. Dr. Selvitelli is currently accepting new patients.

Expertise in
42
conditions
Expertise in
42
conditions
Referral required
Before you request

Office

301C US Route 1, 
Scarborough,, ME 
 (2.4 miles away)
207-883-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tamara Schwartz is a Neurologist practicing medicine in Scarborough,, Maine. Dr. Schwartz is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Multifocal Motor Neuropathy, Distal Median Nerve Dysfunction, Myasthenia Gravis, and Chronic Inflammatory Demyelinating Polyneuropathy. Dr. Schwartz is currently accepting new patients.

Frequently Asked Questions about Dr. Christine Lu-Emerson

How do I make an appointment with Dr. Christine Lu-Emerson?

You can book an appointment with Dr. Christine Lu-Emerson by calling their office at 207-883-1414. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christine Lu-Emerson a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christine Lu-Emerson is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christine Lu-Emerson specialize in?

While Dr. Christine Lu-Emerson is a Neurology, they have specific expertise in Astrocytoma, Metastatic Brain Tumor, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Christine Lu-Emerson participate in research or clinical trials?

Yes. Dr. Christine Lu-Emerson has published 16 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Christine Lu-Emerson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christine Lu-Emerson accept my insurance?

Dr. Christine Lu-Emerson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 207-883-1414 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lu-Emerson's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile